Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

International Business TimesWednesday, November 5, 2025 at 1:08:22 PM

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are currently engaged in a competitive struggle to acquire Metsera, a developer of obesity drugs. This battle is significant as it highlights the growing market for obesity treatments and the lengths major pharmaceutical companies will go to secure innovative solutions. The outcome could reshape the landscape of obesity management and influence future drug development.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
TrumpRx News: Why Donald Trump Struck a Deal With Novo Nordisk's Weight Loss Drugs — And What It Says About America's Obesity Problem
PositiveArtificial Intelligence
Donald Trump has made a significant deal with Novo Nordisk to reduce the price of certain GLP-1 weight loss medications to as low as $149 per month, a drastic decrease from the current average price of $1,000 to $1,350. This move is crucial as it addresses America's growing obesity problem, making effective treatments more accessible to those in need. By lowering costs, more individuals may seek help for weight management, potentially leading to healthier lifestyles and reduced healthcare costs in the long run.